Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, August 11, 2008 at 8:30 a.m. EDT to discuss the second quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-719-9788 (U.S.), 1-719-325-4769 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website,, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Contact: Lauren Fischer, +1-212-531-5965

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
4. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
7. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
9. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals Announces Additions to Management Team
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Champions Oncology, Inc. ... and services to personalize the development and use of ... Chief Executive Officer, will be presenting at the LD ... 4:30pm Pacific Standard Time (PST).  The conference, held at ... Los Angeles, CA , will feature 200 small/micro-cap ...
(Date:11/30/2015)... Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... Genomics, Inc., a leading genome informatics company offering highly ... The San Diego -based company has ... and Co-founder, Ashley Van Zeeland , Ph.D., who is ... of the deal were not disclosed. ...
(Date:11/30/2015)... Florida , November 30, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, today announced it will be presenting at ... on December 1, 2015 at 2.30 PM PT. Dr. ... and Strategic Advisor will be giving the presentation and ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
Breaking Biology Technology:
(Date:11/30/2015)... Nov. 30, 2015  BIOCLAIM announced today that ... year,s Fierce Innovation Awards:  Healthcare Edition, an awards ... , FierceHealthcare , and ... finalist in the category of "Privacy and Cybersecurity." ... --> Photo - ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/20/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... recently interviewed on The RedChip Money Report ... on Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication ...
Breaking Biology News(10 mins):